Literature DB >> 1370169

Stimulation of human T lymphocytes by Leishmania lipophosphoglycan-associated proteins.

D M Russo1, S J Turco, J M Burns, S G Reed.   

Abstract

Lipophosphoglycan (LPG) is a glycoconjugate present on the surface of Leishmania promastigotes that has been reported to promote intracellular survival of these parasites, to protect mice against leishmaniasis, and to elicit T cell responses in infected mice and humans. We investigated whether LPG and its components could elicit proliferative responses and cytokine secretion from leishmaniasis patient PBMC. LPG prepared by standard methods (LPG-1) stimulated patients T cells to proliferate and secrete IFN-gamma. LPG was fractionated into several components. An LPG-1-specific T cell line was shown to respond to the core region but not to the repeating saccharide units. LPG-1 was fractionated to yield an LPG-free- associated protein complex and an LPG-2 fraction that was more than 95% depleted of associated protein. The ability of LPG-2 to stimulate T cells was significantly decreased over that of LPG-1. In contrast, LPG-AP stimulated T cell proliferation and IFN-gamma production. Therefore, proteins associated with LPG were effective in eliciting patient T cell responses, whereas the glycolipid enriched moiety was weakly effective or ineffective at stimulating these responses.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370169

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Heterogeneity of wild Leishmania major isolates in experimental murine pathogenicity and specific immune response.

Authors:  C Kébaïer; H Louzir; M Chenik; A Ben Salah; K Dellagi
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  In vitro responses of human peripheral blood mononuclear cells to whole-cell, particulate and soluble extracts of Leishmania promastigotes.

Authors:  E Telino; P M De Luca; D C S Matos; R B Azeredo-Coutinho; M N Meirelles; F Conceição-Silva; A Schubach; S C F Mendonça
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

Review 3.  The genetics of Leishmania virulence.

Authors:  Eugenia Bifeld; Joachim Clos
Journal:  Med Microbiol Immunol       Date:  2015-06-06       Impact factor: 3.402

4.  Glycosphingolipid antigens of Leishmania (Leishmania) amazonensis amastigotes identified by use of a monoclonal antibody.

Authors:  C L Barbiéri; S Giorgio; A J Merjan; E N Figueiredo
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

5.  Human T-cell activation by 14- and 18-kilodalton nuclear proteins of Leishmania infantum.

Authors:  I Suffia; J F Quaranta; M C Eulalio; B Ferrua; P Marty; Y Le Fichoux; J Kubar
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

Review 6.  Leishmaniases of the New World: current concepts and implications for future research.

Authors:  G Grimaldi; R B Tesh
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

7.  The kinetoplastid membrane protein 11 of Leishmania donovani and African trypanosomes is a potent stimulator of T-lymphocyte proliferation.

Authors:  D L Tolson; A Jardim; L F Schnur; C Stebeck; C Tuckey; R P Beecroft; H S Teh; R W Olafson; T W Pearson
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

8.  A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice.

Authors:  M E Wilson; B M Young; K P Andersen; J V Weinstock; A Metwali; K M Ali; J E Donelson
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

9.  Cloning and structure-function analysis of the Leishmania donovani kinetoplastid membrane protein-11.

Authors:  A Jardim; S Hanson; B Ullman; W D McCubbin; C M Kay; R W Olafson
Journal:  Biochem J       Date:  1995-01-01       Impact factor: 3.857

10.  The Leishmania donovani lipophosphoglycan excludes the vesicular proton-ATPase from phagosomes by impairing the recruitment of synaptotagmin V.

Authors:  Adrien F Vinet; Mitsunori Fukuda; Salvatore J Turco; Albert Descoteaux
Journal:  PLoS Pathog       Date:  2009-10-16       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.